The development of HER2-targeting therapies for GC has been hampered by the heterogeneity of HER2 expression and race, and the intrinsic and/or acquired resistance to HER2-targeting drugs in GC, and there is unmet need for drugs with targets beyond the HER2 pathway and with strong antitumor effects. The gene discussed is ERBB2; the disease is gastric cancer.